Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/28700
Title: | Effect of vedolizumab (anti-alpha 4 beta 7-integrin) therapy on histological healing and mucosal gene expression in patients with UC | Authors: | ARIJS, Ingrid De Hertogh, Gert Lemmens, Bart Van Lommel, Leentje de Bruyn, Magali Vanhove, Wiebe Cleynen, Isabelle Machiels, Kathleen Ferrante, Marc Schuit, Frans Van Assche, Gert Rutgeerts, Paul Vermeire, Severine |
Issue Date: | 2018 | Publisher: | BMJ PUBLISHING GROUP | Source: | GUT, 67(1), p. 43-52 | Abstract: | Objective Lymphocyte recruitment to the inflamed gut is increased in UC. Inhibition of this cell trafficking by vedolizumab (VDZ) was successful in inducing and maintaining remission and in induction of endoscopic mucosal healing. There are no data on histological healing with VDZ. We studied histological changes following VDZ therapy and compared gene expression in patients with UC before and after therapy. Design Forty-one patients with UC from GEMINI I and LTS were studied before and at three time points (weeks 6/12/52) following VDZ therapy. Colonic biopsies were scored using the Geboes index and correlated with Mayo endoscopic subscore. Gene expression was analysed using Affymetrix gene arrays. Results Fifty-five per cent of patients achieving endoscopic healing (= Mayo endoscopic subscore 0-1) with VDZ at the studied time points also had histological healing (= Geboes grade 0-1). In most healers, some residual histological changes (eg, disturbed architecture and increased mononuclear cell infiltrate) were still observed, although this was less at week 52. VDZ restored expression of many inflammatory genes in patients with endoscopic healing only at week 52 and not before. In VDZ healers, the expression of many genes remained dysregulated at weeks 6/12/52 compared with controls. Conclusions VDZ induces histological healing in >50% of patients with endoscopic healing, with maximal effect at week 52. VDZ also restored, although incompletely, the colonic expression of many immunerelated genes in patients with UC achieving endoscopic healing at week 52. However, persistent histological and gene dysregulations did remain even in healers, suggesting that maintenance therapy will be necessary to control the intestinal inflammation. | Notes: | [Arijs, Ingrid; de Bruyn, Magali; Vanhove, Wiebe; Cleynen, Isabelle; Machiels, Kathleen; Ferrante, Marc; Van Assche, Gert; Rutgeerts, Paul; Vermeire, Severine] Katholieke Univ Leuven, Dept Clin & Expt Med, Translat Res Ctr Gastrointestinal Disorders, Leuven, Belgium. [Arijs, Ingrid] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium. [Arijs, Ingrid] Jessa Hosp, Hasselt, Belgium. [De Hertogh, Gert; Lemmens, Bart] Katholieke Univ Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res, Leuven, Belgium. [Van Lommel, Leentje; Schuit, Frans] Katholieke Univ Leuven, Gene Express Unit, Dept Cellular & Mol Med, Leuven, Belgium. [de Bruyn, Magali] Katholieke Univ Leuven, Dept Microbiol & Immunol, Rega Inst Med Res, Leuven, Belgium. [Cleynen, Isabelle; Ferrante, Marc] Katholieke Univ Leuven, Dept Human Genet, Univ Hosp Leuven, Leuven, Belgium. [Van Assche, Gert; Rutgeerts, Paul; Vermeire, Severine] Katholieke Univ Leuven, Dept Gastroenterol & Hepatol, Univ Hosp Leuven, Leuven, Belgium. | Document URI: | http://hdl.handle.net/1942/28700 | ISSN: | 0017-5749 | e-ISSN: | 1468-3288 | DOI: | 10.1136/gutjnl-2016-312293 | ISI #: | 000417778600008 | Rights: | Published by the BMJ Publishing Group Limited. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2019 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
43.full.pdf Restricted Access | Published version | 4.73 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
43
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
112
checked on Oct 10, 2024
Page view(s)
54
checked on Sep 7, 2022
Download(s)
44
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.